Pulsed-field Ablation - Current Impact to Make Big Changes by 2035
Pulsed-field ablation is a promising technique for the treatment of atrial fibrillation. This innovative technology has been proven to be effective and safe in treating patients affected by AF. Studies suggest that PFA is a promising technology for electricity induced pulmonary vein isolation and myocardial ablation, which results in remarkable lesion durability and safety.
The Pulsed field ablation market size is anticipated to grow from US$ 185 million in 2024 to US$ 5,418 million by 2035, growing at a CAGR of 35.9% during the forecast period, till 2035.
Most of the pulsed field ablation catheters are circular in shape. It is worth highlighting that these circular-shaped catheters are considered to be the safest type of ablation catheters with the least reported esophageal or aortic damage. Further, it is worth noting that 92% of the circular catheters use only pulse field energy as the source of ablation. In addition, we came across six investigational devices that employ linear catheters to either deliver the pulsed field energy alone, or in combination with the radiofrequency energy. It is interesting to note that Argá Medtech’s Coherent Sine-burst Electroporation (CSE) consists of an ablation catheter which can be operated in dual configurations, circular as well as linear.
Further, the majority (40) of the devices offered by players engaged in this domain, use pulsed field energy as the source of ablation. This is followed by seven devices capable of toggling between radiofrequency and pulsed field energy sources. This combination provides greater flexibility to perform focal ablation in a point-by-point mechanism, while having the liberty to choose between PF or RF, according to the requirement of the target tissue.
30+ companies, including several startups, are engaged in the development of pulsed field ablation solutions; the r&d efforts are being led by players located in north america
Further, most of the players engaged in this domain are headquartered in North America, followed by those located in Asia-Pacific. Notable examples of companies based in North America include (in alphabetical order) AngioDynamics, CardioFocus, Galvanize Therapeutics, Kardium and Sirona Medical Technologies.
The growing numbers of elderly population across the world has led to a higher prevalence of age-related cardiac disorders such as atrial fibrillation and ventricular tachycardia. Subsequently, the need for a better therapeutic modality for the treatment of such indications has triggered both, the establishment of new players as well as expansion of portfolios of already existing players to offer advanced solutions, which can eliminate the potential risks associated with the conventional treatment methods. Currently, the pulsed field ablation market is dominated by the presence of small players (11-50 employees), followed by mid-sized players (51-200 employees). Further, 85% of the total players are privately funded. On the other hand, five publicly listed companies are engaged in this domain; these are (in alphabetical order) Abbott, Acutus Medical, AngioDynamics, Boston Scientific and Medtronic. Out of the five publicly listed companies, the majority of the firms have an employee strength of more than 1,000.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Pulsed Field Ablation Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/pulsed-field-ablation-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415
[email protected]